FDA OK's Cimzia in ankylosing spondylitis, but rejects axSpA
This article was originally published in Scrip
Executive Summary
UCB won US approval on 18 October to expand the use of Cimzia (certolizumab pegol) as a treatment for adults with active ankylosing spondylitis (AS), an inflammatory disease that can cause some of the vertebrae in the spine to fuse together, making it less flexible, resulting in a hunched-forward posture.